Search Options Stock News and Analysis from Schaeffer's

Top Stock Picks of 2026: Bristol-Myers Squibb

https://www.schaeffersresearch.com/content/analysis/2026/03/20/top-stock-picks-of-2026-bristol-myers-squibb

3/20/2026 9:39 AM

For the final few weeks of the first quarter we're going to highlight one of Schaeffer's top 15 picks for 2026. Today, we have drugmaker Bristol-Myers Squibb Co (NYSE:BMY). To access the entirety of t...

Sneak Peek: 3 Stocks from Our Top Picks of 2026 Report

https://www.schaeffersresearch.com/content/bgs/2025/12/30/sneak-peek-3-stocks-from-our-top-picks-of-2026-report

12/30/2025 11:44 AM

Subscribers to Chart of the Week received this commentary on Sunday, Dec, 28. Hope everyone had a lovely Christmas with friends and family. We now turn to one of the most underrated parts...

3 Pharma Stocks Getting an Intraday Trump Bump

https://www.schaeffersresearch.com/content/news/2025/09/30/3-pharma-stocks-getting-an-intraday-trump-bump

9/30/2025 3:19 PM

Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX." The new platform will enable Americans to buy th...

Pharma Stock Rises on Cleared Schizophrenia Treatment

https://www.schaeffersresearch.com/content/news/2024/09/27/pharma-stock-rises-on-cleared-schizophrenia-treatment

9/27/2024 11:43 AM

Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy. This marks the first new treatme...

Analyst: Positive Catalysts Can't Save This Pharma Stock

https://www.schaeffersresearch.com/content/news/2024/02/06/analyst-positive-catalysts-cant-save-this-pharma-stock

2/6/2024 9:00 AM

Biopharmaceutical stock Bristol-Myers Squibb Co (NYSE:BMY) is in focus this morning, after a downgrade to "neutral" from "buy" at Redburn-Atlantic. The analyst in coverage also lowered its price targe...

PEOPLE ALSO SEARCH FOR